Pharmaceutical News

RSS

Lovastatin protects animals against plague

An experimental study has revealed that lovastatin, a drug prescribed for the treatment of hypercholesterolemia, protects animals against the deadly effects of plague. This infectious disease is on the upsurge in parts of the world. These results obtained by scientists at the Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (CNRS/Université Aix-Marseille 2) have been published in the journal PLoS ONE.

4 Jun 2010

Multiple sclerosis risk sharing scheme: A costly failure

The multiple sclerosis risk sharing scheme is "a costly failure" and should not be continued, according to researchers on bmj.com today. They argue that the biggest losers are the other NHS patients who would otherwise have benefited from the money spent on the scheme, estimated to be around -50m per year since it was set up in 2002.

4 Jun 2010

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

The liver scarring of α1-antitrypsin deficiency, the most common genetic cause for which children undergo liver transplantation, might be reversed or prevented with a medication that has long been used to treat seizures, according to findings from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine that will published in Science and are available online today through the Science Express website.

4 Jun 2010

New therapy mounts double-barreled attack on leukemia, report UF researchers

A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

4 Jun 2010

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

Hiru Corporation and its European subsidiary MindUp BioResearch comment on the recent research findings in the field of cancer treatments for multi-drug resistant non-small cell lung cancer.

4 Jun 2010

ViiV Healthcare to provide additional cost savings to cash-strapped ADAPs

AHF is pleased to report that yet another drug company: ViiV Healthcare, a new drug company formed in a partnership between GSK and Pfizer, has announced an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide.

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

European countries focus on drug price cuts

"European governments grappling to reduce large budget deficits are focusing their cost-cutting on a large spending item — pharmaceuticals," The Wall Street Journal reports. "Several countries in recent weeks, including Spain, Germany and Italy, have proposed or enacted reductions in what they will pay or taken other cost-control measures for various drugs.

4 Jun 2010

FDA approves Perrigo's ANDA for OTC Miconazole Nitrate Vaginal Cream and Suppository

Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter (OTC) Miconazole Nitrate Vaginal Cream and Suppository, a generic to Monistat® -1 Combination Pack. Perrigo expects to begin shipping immediately.

4 Jun 2010

Antiviral drug oseltamivir appears safe and effective for infants hospitalized with influenza: Study

Given promptly, the antiviral drug oseltamivir (Tamiflu) appears safe and effective for infants hospitalized with influenza, reports a study in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

4 Jun 2010

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences Ltd. and Pan-Provincial Vaccine Enterprise Inc. of Saskatoon, Saskatchewan, today announced that the two groups have entered into a licensing agreement granting PREVENT exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis vaccines.

3 Jun 2010

Taro's granisetron tablets receive FDA approval

Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").

3 Jun 2010

Local anesthetics may have potential therapeutic effects on IBD

Inflammatory bowel disease (IBD) is a disease of the gastrointestinal tract, mainly the intestines that may occur in the people who have genetic potential with a contribution of environmental factors.

3 Jun 2010

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis.

3 Jun 2010

Biovail: BLS, Kyowa Hakko Kirin sign license agreement

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL, has entered into a license agreement with Kyowa Hakko Kirin Co., Ltd. BLS has acquired the U.S. and Canadian rights to commercialize products containing istradefylline - a new chemical entity targeted for the treatment of Parkinson's disease.

3 Jun 2010

Medical marijuana hydroponics nutrients receive official US approval

In a landmark decision, Oregon regulators have given first-ever official US approval to a brand of medical marijuana hydroponics nutrients. Oregon and most other states have regulatory agencies that examine fertilizers and hydroponics plant supplements to determine the legitimacy, ingredients and effectiveness of plant growth products.

3 Jun 2010

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

GlaxoSmithKline today announced that it has received a letter from the U.S. Food and Drug Administration directing revisions to product labeling for its respiratory products Serevent and Advair. The letter concludes discussions between GSK and the agency following FDA advisory committee meetings regarding the safety profile of long-acting beta2-agonists in the treatment of asthma, including salmeterol, the active ingredient in Serevent and one of the active ingredients in Advair.

3 Jun 2010

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

MedImmune today announced that the U.S. Food and Drug Administration's Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus disease in high-risk infants.

3 Jun 2010

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, announced today that the company's highly selective oral kinase inhibitor, Telatinib, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of gastric cancer.

3 Jun 2010

Insulin pills to manage diabetes are finally moving ahead in clinical trials

After years of research and anticipation, insulin pills that could make it easier for millions of patients worldwide to manage diabetes are finally moving ahead in clinical trials and a step-closer to the medicine cabinet. That's among the topics highlighted in a two-part cover story on drug manufacturing in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

3 Jun 2010

Pharmaceutical News

Lovastatin protects animals against plague

Multiple sclerosis risk sharing scheme: A costly failure

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

New therapy mounts double-barreled attack on leukemia, report UF researchers

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

ViiV Healthcare to provide additional cost savings to cash-strapped ADAPs

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

European countries focus on drug price cuts

FDA approves Perrigo's ANDA for OTC Miconazole Nitrate Vaginal Cream and Suppository

Antiviral drug oseltamivir appears safe and effective for infants hospitalized with influenza: Study

Amorfix Life Sciences signs licensing agreement with PREVENT

Taro's granisetron tablets receive FDA approval

Local anesthetics may have potential therapeutic effects on IBD

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Biovail: BLS, Kyowa Hakko Kirin sign license agreement

Medical marijuana hydroponics nutrients receive official US approval

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

Insulin pills to manage diabetes are finally moving ahead in clinical trials

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News